AbbVie has announced a $380 million investment to construct two new active‑pharmaceutical‑ingredient (API) manufacturing facilities on its North Chicago, Illinois campus. The state‑of‑the‑art plants will begin construction in spring 2026 and are slated to be fully operational by 2029, adding significant domestic production capacity for the company’s next‑generation neuroscience and obesity medicines.
The new facilities will integrate advanced manufacturing technologies and artificial intelligence, enabling higher throughput, tighter quality control, and faster scale‑up of complex molecules. This technology focus is intended to support AbbVie’s expanding pipeline in neuroscience and obesity, areas where the company is investing heavily to replace the revenue that has been eroded by Humira’s loss of exclusivity.
AbbVie plans to hire 300 employees in North Chicago, including engineers, scientists, manufacturing operators and lab technicians. The workforce expansion reflects the company’s commitment to building a skilled domestic manufacturing base and to sustaining the production of its high‑margin specialty drugs.
The investment is part of AbbVie’s broader $100 billion commitment to U.S. research, development and capital investments over the next decade, a pledge made in a voluntary agreement with the U.S. administration in January 2026. The new plants follow a $195 million expansion of chemical synthesis capabilities in August 2025 and align with the company’s strategy to reshore production, reduce supply‑chain risk and take advantage of domestic manufacturing incentives.
Financially, AbbVie reported a Q4 2025 earnings beat, with adjusted EPS of $2.71 versus an estimate of $2.66 and revenue of $16.62 billion versus $16.39 billion. The company’s full‑year 2025 adjusted EPS was $10.00 on net revenues of $61.16 billion, and it has guided FY 2026 adjusted EPS to $14.37–$14.57, above the consensus of $14.32. The strong results were driven by robust growth in immunology products such as Skyrizi and Rinvoq, while the company continues to navigate headwinds from Humira’s sales erosion. The new manufacturing capacity is positioned to support the launch of future neuroscience and obesity drugs, reinforcing AbbVie’s confidence in its pipeline and its ability to maintain profitability amid a shifting market landscape.
"This milestone demonstrates further progress against our $100 billion commitment to U.S. R&D and capital investments over the next decade," said Robert A. Michael, AbbVie’s chairman and chief executive officer. "By strengthening our U.S. manufacturing capabilities, we are well‑positioned to support our investment in innovation and enhance our ability to deliver next‑generation medicines to patients."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.